In view of the potential role of TMED9 as an oncogene in GBM, and the identification of a TMED9-targeting compound, we aimed to (i) study the expression and function of TMED9 in GSCs and (ii) investigate the effects of pharmacologically targeting TMED9 using BRD4780 as a potential anti-tumor treatment. Here, TMED9 is linked to glioblastoma.